Opthea (NASDAQ:OPT – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Opthea to post earnings of ($0.43) per share for the quarter.
Opthea Stock Down 3.3 %
OPT opened at $5.04 on Wednesday. The stock’s 50 day moving average price is $4.27 and its 200-day moving average price is $3.85. Opthea has a one year low of $1.79 and a one year high of $6.30.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Opthea in a research note on Wednesday, January 29th. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research note on Tuesday, December 17th.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More
- Five stocks we like better than Opthea
- Short Selling – The Pros and Cons
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Stock Analyst Ratings and Canadian Analyst Ratings
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What is MarketRank™? How to Use it
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.
